These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile? Olieman AF; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ Arch Orthop Trauma Surg; 1998; 118(1-2):70-4. PubMed ID: 9833110 [TBL] [Abstract][Full Text] [Related]
5. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis. Plaat BE; Molenaar WM; Mastik MF; Koudstaal J; van den Berg E; Koops HS; Hoekstra HJ Clin Cancer Res; 1999 Jul; 5(7):1650-7. PubMed ID: 10430064 [TBL] [Abstract][Full Text] [Related]
6. Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Komdeur R; Plaat BE; Hoekstra HJ; Molenaar WM; Hollema H; van den Berg E; Mastik MF; van der Graaf WT Cancer; 2001 May; 91(10):1940-8. PubMed ID: 11346877 [TBL] [Abstract][Full Text] [Related]
7. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient. Bonvalot S; Rimareix F; Causeret S; Le Péchoux C; Boulet B; Terrier P; Le Cesne A; Muret J Ann Surg Oncol; 2009 Dec; 16(12):3350-7. PubMed ID: 19830495 [TBL] [Abstract][Full Text] [Related]
8. L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer. van Ginkel RJ; Kole AC; Nieweg OE; Molenaar WM; Pruim J; Koops HS; Vaalburg W; Hoekstra HJ J Nucl Med; 1999 Feb; 40(2):262-7. PubMed ID: 10025833 [TBL] [Abstract][Full Text] [Related]
9. Hyperthermic isolated limb perfusion in locally advanced limb soft tissue sarcoma: A 24-year single-centre experience. Rastrelli M; Campana LG; Valpione S; Tropea S; Zanon A; Rossi CR Int J Hyperthermia; 2016; 32(2):165-72. PubMed ID: 26608883 [TBL] [Abstract][Full Text] [Related]
10. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Olieman AF; Liénard D; Eggermont AM; Kroon BB; Lejeune FJ; Hoekstra HJ; Koops HS Arch Surg; 1999 Mar; 134(3):303-7. PubMed ID: 10088573 [TBL] [Abstract][Full Text] [Related]
11. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations. Issakov J; Merimsky O; Gutman M; Kollender Y; Lev-Chelouche D; Abu-Abid S; Lifschitz-Mercer B; Inbar M; Klausner JM; Meller I Ann Surg Oncol; 2000 Mar; 7(2):155-9. PubMed ID: 10761796 [TBL] [Abstract][Full Text] [Related]
12. Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study. Lasithiotakis K; Economou G; Gogas H; Ioannou C; Perisynakis K; Filis D; Kastana O; Bafaloukos D; Decatris M; Catodritis N; Frangia K; Papadakis G; Magarakis M; Tsoutsos D; Chrysos E; Chalkiadakis G; Zoras O Oncol Rep; 2010 Apr; 23(4):1077-83. PubMed ID: 20204294 [TBL] [Abstract][Full Text] [Related]
14. The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-α: a comparison with the whole group of resected soft tissue sarcomas. Schwindenhammer B; Podleska LE; Kutritz A; Bauer S; Sheu SY; Taeger G; Schmid KW; Grabellus F World J Surg Oncol; 2013 Aug; 11(1):185. PubMed ID: 23938063 [TBL] [Abstract][Full Text] [Related]
15. Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities. Schraffordt Koops H; Eggermont AM; Liènard D; Kroon BB; Hoekstra HJ; van Geel AN; Nieweg OE; Lejeune FJ Radiother Oncol; 1998 Jul; 48(1):1-4. PubMed ID: 9756165 [TBL] [Abstract][Full Text] [Related]
16. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO). Di Filippo F; Giacomini P; Rossi CR; Santinami M; Garinei R; Anzà M; Deraco M; Botti C; Perri P; Cavaliere F; Di Angelo P; Sofra C; Sperduti I; Pasqualoni R; Di Filippo S; Corrias F; Armenti A; Ferraresi V In Vivo; 2009; 23(2):363-7. PubMed ID: 19414428 [TBL] [Abstract][Full Text] [Related]
17. Hyperthermic isolated limb perfusion in the management of extremity sarcoma. Hoekstra HJ; van Ginkel RJ Curr Opin Oncol; 2003 Jul; 15(4):300-3. PubMed ID: 12874508 [TBL] [Abstract][Full Text] [Related]
18. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors. Vrouenraets BC; Keus RB; Nieweg OE; Kroon BB J Surg Oncol; 1997 Jun; 65(2):88-94. PubMed ID: 9209519 [TBL] [Abstract][Full Text] [Related]